# Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

> **NCT03586999** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 18 (actual)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Etoposide
- **DRUG:** Prednisolone
- **DRUG:** Oncovin
- **DRUG:** Cyclophosphamide
- **DRUG:** Hydroxydaunorubicin

## Key facts

- **NCT ID:** NCT03586999
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-07
- **Primary completion:** 2021-05-26
- **Final completion:** 2022-09-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03586999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03586999, "Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03586999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*